European Journal of Haematology最新文献

{"title":"Νοvel Therapies in High-Risk Myelodysplastic Syndromes.","authors":"Athanasios G Galanopoulos, Christina Papi","doi":"10.1111/ejh.70146","DOIUrl":"10.1111/ejh.70146","url":null,"abstract":"<p><p>Myelodysplastic syndromes/neoplasms (MDS) constitute a very heterogeneous group of clonal myeloid neoplasms characterized by a variable clinical course and recurrent genetic abnormalities. Their treatment relies on risk classification as lower or higher-risk categories by the original International Prognostic Scoring System (IPSS) or the current revised (IPSS-R) or molecular IPSS-M. Higher-risk MDS (HR-MDS) are clonal hematopoietic disorders characterized by significant cytopenias, dysplastic changes, and a high propensity for progression to acute myeloid leukemia (AML). Up to 40% of them usually progress to AML within two years of diagnosis. Allogeneic stem cell transplantation (HSCT) remains the only potential cure and standard of care for eligible patients. Despite standard treatments such as Allo-HSCT and hypomethylating agents (HMAs), outcomes remain suboptimal. Recent advances have led to the development of novel therapeutic strategies, such as BCL-2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, enasidenib), CD47 inhibitors (magrolimab), TIM-3 inhibitors (sabatolimab), XPO1 inhibitors (eltanexor), NEDD8-activating enzyme inhibitors (pevonedistat), TP53-targeted agents (eprenetapopt), liposomal chemotherapy (CPX-351), and oral HMA formulations. Combinations of hypomethylating agents with these new drugs, as first-line treatment, have to date not proven more efficacious than HMA monotherapy. This review summarizes the current therapeutic landscape on novel therapies for HR-MDS, highlighting their mechanism of action, efficacy, and demonstrates the unmet clinical need for more effective therapies.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"744-758"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147283242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives.","authors":"Gianluca Gaidano, Romano Danesi","doi":"10.1111/ejh.70144","DOIUrl":"10.1111/ejh.70144","url":null,"abstract":"<p><p>Acalabrutinib, a second-generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off-target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site, ensures potent and sustained blockade of B cell receptor signaling, leading to disruption of key survival and proliferation pathways in malignant B cells. Long-term data from pivotal phase III trials confirmed the high efficacy of acalabrutinib-containing regimens in both treatment-naïve and relapsed/refractory CLL, showing durable progression-free survival, favorable overall survival rates, and low incidence of serious adverse events such as atrial fibrillation and hypertension, likely attributable to its improved selectivity, with limited immunosuppression and better tolerability leading to lower discontinuation rates compared to first-generation BTKi. Fixed-duration combination with acalabrutinib plus venetoclax, with or without obinutuzumab, has recently emerged as a highly efficacious strategy, providing sustained minimal residual disease (MRD) negativity with manageable toxicity, further supporting the clinical utility of acalabrutinib regimens. The demonstrated efficacy, robust safety, and flexibility of acalabrutinib in both continuous and fixed-duration regimens make it a cornerstone for individualized CLL management, enabling tailored treatment approaches based on patient- and disease-specific factors.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"759-770"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13141669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147283250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM.","authors":"Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile","doi":"10.1111/ejh.70134","DOIUrl":"10.1111/ejh.70134","url":null,"abstract":"<p><p>Multiple myeloma (MM) remains an incurable plasma cell malignancy characterized by recurrent relapses and eventual refractoriness to standard agents, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies. With frontline therapeutic strategies increasingly employing quadruplet induction regimens and prolonged lenalidomide maintenance, resistance to traditional IMiDs has become more prevalent, creating an urgent need for next-generation cereblon E3 ligase modulators (CELMoDs) capable of overcoming IMiD refractoriness and enhancing the immunologic microenvironment. Iberdomide (CC-220) and mezigdomide (CC-92480) are rationally engineered CELMoDs designed to achieve deeper degradation of Ikaros (IKZF1) and Aiolos (IKZF3), restore cereblon-mediated activity, and potentiate immune effector responses. This review explores the core biological features of these agents, detailing their mechanisms of action, preclinical and clinical activity, as well as safety profile. We examine how their pharmacodynamic properties differ from classical IMiDs, their relevance in triple-class and penta-refractory MM, and their integration into emerging combination strategies with monoclonal antibodies and T-cell-redirecting immunotherapies. Special emphasis is placed on ongoing and future trials that may refine their therapeutic positioning, alongside a critical appraisal of the limitations and future directions of this rapidly advancing drug class.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"697-708"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13141667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Anemia in Solid and Hematologic Malignancies: A Comprehensive Review of Classical and Emerging Therapies.","authors":"Lauryn K Bailey, Hannah Mahjoub, Corinne LaVasseur, Jacob M Berkowitz, Beatrice E Torere, Lukas V Seifer, Aditya K Malhotra, Joseph J Shatzel","doi":"10.1111/ejh.70135","DOIUrl":"10.1111/ejh.70135","url":null,"abstract":"<p><p>Anemia frequently complicates cancer care, leading to reduced quality of life and poorer overall prognosis. Even mild-to-moderate anemia in cancer patients has been associated with worse outcomes, including increased fatigue, physical decline, and decreased tolerance to cancer therapies. Importantly, studies have demonstrated that correcting anemia and improving hemoglobin levels can significantly alleviate fatigue, enhance emotional well-being, and improve overall quality of life. An improved understanding of the underlying mechanisms of cancer-related anemia has led to the development of a range of therapeutic strategies, from traditional supportive measures to innovative targeted therapies. In the following manuscript, we provide an in-depth review of these approaches, beginning with established treatments and progressing to newer investigational therapies and specialized strategies for patients with solid tumors and hematologic malignancies. This framework aims to guide clinicians in selecting and tailoring anemia management to improve outcomes and quality of life for patients across cancer types.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"709-723"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rate of MGUS Progression to Haematological Malignancies: A Systematic Review.","authors":"Stephen James Quinn, Chris Cardwell, Lesley Ann Anderson, Charlene McShane","doi":"10.1111/ejh.70086","DOIUrl":"10.1111/ejh.70086","url":null,"abstract":"<p><p>Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre-cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely. To address this discrepancy, a systematic review was conducted, investigating MGUS's rate of malignant progression to HM and MM alone. Four electronic databases were searched from inception to 28 March 2024 for articles reporting these outcomes; articles were summarised using meta-analysis and narrative synthesis. Findings were incorporated from n = 46 studies, published between 1991 and 2024 and conducted across n = 17 countries. Median follow-up ranged from 1.3 to 34.2 years and sample sizes ranged from n = 63 to 17,963. In random-effects meta-analysis, n = 13 studies reported on MGUS progression to HM and n = 12 reported on progression to MM. The overall estimates of malignant progression events were 12 per 1000 person-years to HM, equivalent to 1.2% per year (95% CI: 1.0%-1.5%) and 8 per 1000 person-years to MM or 0.8% per year (95% CI: 0.7%-1.1%), with substantial heterogeneity between studies (I²: 96.7% and 95.8%, respectively). Progression rates varied widely in narrative synthesis; at 10 years, studies reported annual MGUS progression rates of 6.6%-33.6% to HM and 7.0%-28.5% to MM. While progression rates aligned with clinical guidelines overall, studies' varied findings present opportunities for further research, exploring the impact of world region, follow-up duration, and study methods. Considering this, caution should be taken when informing clinicians and patients about the risk of progression from MGUS to MM.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"889-906"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13141670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naïve Fit Patients With CLL Without TP53 Aberrations.","authors":"Lars Holger Ehlers, Mark-David Levin, Marjolein van der Klift, Morten Berg Jensen, Hoa Thi Tuyet Tran, Arnon P Kater, Carsten Utoft Niemann","doi":"10.1111/ejh.70143","DOIUrl":"10.1111/ejh.70143","url":null,"abstract":"<p><p>The GAIA-CLL13 trial showed that venetoclax-obinutuzumab (Ven-O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment-naïve (TN) CLL patients. However, their higher costs warrant a cost-effectiveness evaluation. This study assessed the cost-effectiveness of Ven-O versus venetoclax with rituximab (Ven-R), venetoclax-obinutuzumab-ibrutinib (Ven-O-I), and CIT in fit, TN CLL patients without TP53 aberrations across the Netherlands, Norway, and Denmark. A state-transition Markov model including later line treatment was applied to estimate costs, life years (LYs), and quality-adjusted life years (QALYs) over a 38-year horizon. Results were sensitive to long-term OS assumptions. In the base-case analysis, extrapolating OS and PFS for each treatment separately, all venetoclax-based treatments appeared cost-effective compared to CIT in all three countries. ICERs for Ven-R, Ven-O, and Ven-O-I versus CIT were €35 840, €32 513, €30 331 for the Netherlands, €39 881, €38 099, €26 381 for Norway, and €34 010, €37 804, €33 215 for Denmark. In the sensitivity analyses, however, cost-effectiveness was lost when only allowing separate OS and PFS extrapolations for statistically significant differences at 60-month follow-up. Furthermore, cost-effectiveness results were sensitive to varying assumptions about national willingness-to-pay (WTP) thresholds, IGHV-status, and time horizon. In conclusion, venetoclax-based treatments may be considered a cost-effective treatment option for fit, TN CLL patients without TP53 aberrations in the Netherlands, Norway, and Denmark, but the pricing process for targeted agents should take the uncertainty about cost-effectiveness into account when negotiating pricing of medication. Longer follow-up data is needed to address the uncertainties.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"873-882"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13141661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.","authors":"Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox-Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin","doi":"10.1111/ejh.70137","DOIUrl":"10.1111/ejh.70137","url":null,"abstract":"<p><strong>Introduction: </strong>Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time-limited regimens such as venetoclax-obinutuzumab (Ven-O) and ibrutinib-venetoclax (I + V). However, factors guiding first-line treatment decisions in routine practice remain poorly defined.</p><p><strong>Objectives: </strong>To describe real-world first-line treatment patterns and identify factors associated with therapy selection.</p><p><strong>Methods: </strong>This retrospective, population-based study included consecutive patients initiating first-line therapy for CLL/SLL in 2024 in Alberta, Canada.</p><p><strong>Results: </strong>Among 148 patients with median age 71 years, time-limited targeted therapy was selected for 75 (51%), including Ven-O (n = 73) and I + V (n = 2). Continuous BTKi therapy was used in 65 (44%), while chemotherapy-based regimens were uncommon (n = 8, 5%). Among 138 patients treated with either continuous BTKi or Ven-O, BTKi use was significantly more frequent among those with del(17p)/TP53 mutation (84% vs. 16%, p = 0.0002), age > 75 years (66% vs. 34%, p = 0.0051), and residence > 100 km from an obinutuzumab-initiating cancer center (70% vs. 30%, p = 0.031).</p><p><strong>Conclusions: </strong>Time-limited and continuous targeted therapies are used with similar frequency for CLL/SLL, with selection shaped by age, TP53 aberrations, geography, and patient preferences. These findings highlight the importance of personalized care and the need to reduce access barriers to time-limited strategies.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"845-849"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13141657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome-Wide Meta-Analysis of 1 896 991 Individuals Identifies 31 Novel Risk Loci for Iron Deficiency Anemia.","authors":"Ran Gao, Wenting Su, Jiahui Deng, Bing Zhai, Gaizhi Zhu, Jinming Qiu, Ziqing Bian, He Xiao, Guoming Luan, Renxi Wang","doi":"10.1111/ejh.70128","DOIUrl":"10.1111/ejh.70128","url":null,"abstract":"<p><strong>Objectives: </strong>Our aim was to gain deeper insight into the genetic susceptibility of iron deficiency anemia (IDA).</p><p><strong>Methods: </strong>We performed the first multi-ancestry meta-analysis of genome-wide association study (GWAS), which included 113 055 IDA cases and 1 783 936 healthy controls.</p><p><strong>Results: </strong>Through multi-ancestry meta-analysis, 31 risk loci were identified, alongside 703 candidate genes indicated and 47 genes prioritized for IDA. Heritability analyses demonstrated that the liability scale heritability was 3.1% ± 0.2%, whereas an estimated 43.92 million effective sample size would be required to explain 90% of the phenotypic variance. Gene enrichment analysis, gene-set analyses, and genetic correlation studies revealed that IDA-related genes were enriched in whole blood, influenced the role of HFE (hemochromatosis gene) in regulating systemic iron homeostasis, and showed positive correlations with inflammatory diseases, psychological diseases, and cardiovascular diseases. Finally, gene-based prioritized analysis and gene-drug interaction analysis identified some potential targets (e.g., BLK), while drug repurposing approaches highlighted exploratory drug candidates (e.g., folic acid) for IDA.</p><p><strong>Conclusion: </strong>We identified 31 novel risk loci for IDA and further characterized its genetic architecture.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"785-796"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced- Versus Extended-Dose Anticoagulation for Venous Thromboembolism in Patients With and Without Cancer: A Systematic Review and Meta-Analysis.","authors":"Muhammad Faizan Ali, Faisal Naseer, Ahmed W Hageen, Shariq Hayat, Zarwa Rashid, F N U Momna, F N U Sawaira, Abdul Ahad Riaz, Husnain Ahmad, Sherif Eltawansy, Mohammad Hossain, Tarique Ahmed, Muhammad Abdullah Naveed, Muhammad Bilal Munir, Himaja Dutt Chigurupati, Yasar Sattar, Sivaram Neppala","doi":"10.1111/ejh.70142","DOIUrl":"10.1111/ejh.70142","url":null,"abstract":"<p><strong>Background: </strong>Extended-duration anticoagulation reduces recurrent venous thromboembolism (VTE) in cancer and non-cancer patients. Reduced-dose direct oral anticoagulants (DOACs) may be safer if they match efficacy with less bleeding risk. We conducted a systematic review and meta-analysis of trials comparing reduced-dose and extended-dose DOACs.</p><p><strong>Methods: </strong>Randomized controlled trials comparing reduced-dose with extended-dose anticoagulation for secondary VTE prevention were systematically reviewed. Primary outcomes included recurrent symptomatic VTE, pulmonary embolism (PE), and deep vein thrombosis (DVT). Secondary outcomes included bleeding, adverse events, and all-cause mortality. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Subgroup and leave-one-out sensitivity analyses explored heterogeneity and robustness. All analyses were conducted in R (version 4.3.1).</p><p><strong>Results: </strong>Six RCTs (n = 9382) were included. Reduced-dose anticoagulation showed no statistically significant difference in recurrent VTE (RR 0.98, 95% CI 0.72-1.33), PE (RR 0.96, 95% CI 0.61-1.50), or DVT (RR 0.86, 95% CI 0.56-1.32) compared with extended-dose therapy. Major bleeding was significantly reduced (RR 0.68, 95% CI 0.48-0.98), as were clinically relevant non-major bleeding and any bleeding. All-cause mortality did not differ significantly. Heterogeneity was low to moderate across outcomes, and sensitivity analyses confirmed the stability of results.</p><p><strong>Conclusion: </strong>Reduced-dose anticoagulation demonstrated similar efficacy with improved safety compared with extended-dose therapy. These findings support individualized dose reduction strategies after extended anticoagulation.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: CRD420251081952.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"863-872"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147270254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excess Mortality of Warm Autoimmune Haemolytic Anaemia: Unrecognised and Unmet Real-World Needs.","authors":"Jun Yen Ng, Ry Cambourne, Meidelynn Ooi, Saratkrishna Menon, Phil Choi","doi":"10.1111/ejh.70147","DOIUrl":"10.1111/ejh.70147","url":null,"abstract":"","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":"945-948"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}